APAC Healthcare Weekly (April 27)- Sillajen, Akeso, Innovent Biologics, CSL, Daiichi Sankyo, Lupin
SillaJen got FDA nod for clinical trial indication expansion. FDA approves Akeso’s first drug. Innovent’s cancer drug was approved in China....
662 Views
End of Mandatory Lock-Up Periods for 52 Companies in Korea in February 2023
We discuss end of the mandatory lock-up periods for 52 stocks in Korea in February 2023, among which 3 are in KOSPI and 49 are in KOSDAQ.
425 Views
Can You Profit from the KR Retail Investor? (Btw You Already Probably Have Met Him)
I wanted to share my thoughts as I follow the retail moves and share not only who the powerful or mover/shaker Korean retail investor as they now...
618 Views
Final Bi-Annual Rebalance Announced for KOSPI200, KOSDAQ150, & KRX300
The Korea Exchange announced its bi-annual changes to KOSPI200 today. These changes are effective 12 June 2020. For the KOSPI200, there were 11...
548 Views
EM Managers: Most Avoided Stocks - 2018 Update
In this report, we screen for stocks that are largely avoided by global emerging market active funds. We identify companies within the MSCI...
340 Views